Comparison of the capability of GDNF, BDNF, or both, to protect nigrostriatal neurons in a rat model of Parkinson's disease. - Wikidata - wikimedia - TriplyDB

Comparison of the capability of GDNF, BDNF, or both, to protect nigrostriatal neurons in a rat model of Parkinson's disease.

Comparison of the capability of GDNF, BDNF, or both, to protect nigrostriatal neurons in a rat model of Parkinson's disease.

http://www.wikidata.org/entity/Q36969309

about

Phosphodiesterase Inhibition and Regulation of Dopaminergic Frontal and Striatal Functioning: Clinical Implications Neurotrophic factors as a therapeutic target for Parkinson's disease Neuroregeneration in neurodegenerative disorders.Enhanced nigrostriatal neuron-specific, long-term expression by using neural-specific promoters in combination with targeted gene transfer by modified helper virus-free HSV-1 vector particles.Viral vectors for neurotrophic factor delivery: a gene therapy approach for neurodegenerative diseases of the CNS Gene delivery with viral vectors for cerebrovascular diseases.Zirconium oxide ceramic foam: a promising supporting biomaterial for massive production of glial cell line-derived neurotrophic factor Brain-derived neurotrophic factor suppresses tunicamycin-induced upregulation of CHOP in neurons.Neurotensin-polyplex-mediated brain-derived neurotrophic factor gene delivery into nigral dopamine neurons prevents nigrostriatal degeneration in a rat model of early Parkinson's disease.Intracarotid Infusion of Mesenchymal Stem Cells in an Animal Model of Parkinson's Disease, Focusing on Cell Distribution and Neuroprotective and Behavioral Effects.Trophic factors GDNF and BDNF improve function of retinal sheet transplants Transgene expression in the striatum following intracerebral injections of DNA nanoparticles encoding for human glial cell line-derived neurotrophic factor.Exercise copes with prolonged stress-induced impairment of spatial memory performance by endoplasmic reticulum stress.Efficient Expression of Igf-1 from Lentiviral Vectors Protects In Vitro but Does Not Mediate Behavioral Recovery of a Parkinsonian Lesion in Rats.Shedding light into the role of BDNF in the pharmacotherapy of Parkinson's disease.HSV-1 amplicon vectors: a promising and versatile tool for gene delivery.Frontiers in the surgical treatment of Parkinson's disease.GDNF therapy for Parkinson's disease.FTY720/Fingolimod Reduces Synucleinopathy and Improves Gut Motility in A53T Mice: CONTRIBUTIONS OF PRO-BRAIN-DERIVED NEUROTROPHIC FACTOR (PRO-BDNF) AND MATURE BDNF.Decreased expression of ErbB4 and tyrosine hydroxylase mRNA and protein in the ventral midbrain of aged rats.Challenges and opportunities in CNS delivery of therapeutics for neurodegenerative diseases.Functional mechanism of neuroprotection by inhibitors of type B monoamine oxidase in Parkinson's disease.Delayed transplantation of precursor cell-derived astrocytes provides multiple benefits in a rat model of Parkinsons.Viral vectors for gene delivery to the central nervous system.Revelation in the neuroprotective functions of rasagiline and selegiline: the induction of distinct genes by different mechanisms.Gene therapy for the treatment of Parkinson's disease: the nature of the biologics expands the future indications Does PGC1α/FNDC5/BDNF Elicit the Beneficial Effects of Exercise on Neurodegenerative Disorders?A 16 bp upstream sequence from the rat tyrosine hydroxylase promoter supports long-term expression from a neurofilament promoter, in a helper virus-free HSV-1 vector system.Enhanced efficacy of the CDNF/MANF family by combined intranigral overexpression in the 6-OHDA rat model of Parkinson's disease.Neuroprotective potential of pleiotrophin overexpression in the striatonigral pathway compared with overexpression in both the striatonigral and nigrostriatal pathways.Neurotrophin Signaling and Stem Cells-Implications for Neurodegenerative Diseases and Stem Cell Therapy.Stimulation of the rat subthalamic nucleus is neuroprotective following significant nigral dopamine neuron loss.Electrical stimulation of the dorsal columns of the spinal cord for Parkinson's disease.The vesicular glutamate transporter-1 upstream promoter and first intron each support glutamatergic-specific expression in rat postrhinal cortex.Genetic labeling of both the axons of transduced, glutamatergic neurons in rat postrhinal cortex and their postsynaptic neurons in other neocortical areas by herpes simplex virus vectors that coexpress an axon-targeted β-galactosidase and wheat germ Antibody-mediated targeted gene transfer to NMDA NR1-containing neurons in rat neocortex by helper virus-free HSV-1 vector particles containing a chimeric HSV-1 glycoprotein C-staphylococcus A protein Alginate-matrigel microencapsulated schwann cells for inducible secretion of glial cell line derived neurotrophic factor.Herpes Virus Amplicon Vectors.Role of glial cell derived neurotrophic factor in the protective effect of smilagenin on rat mesencephalic dopaminergic neurons damaged by MPP+.Protection of dopaminergic neurons by electroconvulsive shock in an animal model of Parkinson's disease.

P2860

Q26753116-B5FE5A87-49B9-41F8-9B11-3C7D47DBF3D4 Q28273071-E7CAC73C-31B7-45FE-90DC-D1A092BFFC9D Q31020342-CCDADE14-6B0D-4C26-BFC9-2088395A2863 Q33327584-57FD2831-81F8-458B-BE91-610EB254AA8E Q33894621-815A3A5A-6CD6-4942-8710-6D71B1C75A20 Q33917592-8113C26D-DF74-40B0-B765-3F99A9CBEE36 Q34696178-48C2C7FA-FFD2-40AB-93A4-F87277FCDD5D Q34903552-8479D1C6-44F0-4D85-8B25-BE3C20567A92 Q35878528-3E691F44-8313-4D09-8017-36D9040FA1DE Q35975405-98EAD440-BA62-4C05-A508-F3391F8666E8 Q36042299-CF126F51-84A9-41FE-B297-3169E12D5228 Q36128982-016115AC-46DC-41F7-BC0B-74C62D66AA3A Q36218602-C9833016-95FB-4E4B-A5BD-A6B94A50C97E Q36294787-C62CA686-D51E-4697-8074-C54A2CA9053A Q36364388-09E07803-EE77-4D00-9D4D-260959FE6BEC Q36897379-61F729EF-EAEF-4D01-AB0C-51785908F3EF Q37174039-05F152C0-5E26-4F52-94A6-3FA2760D1E31 Q37203371-6BF46B4B-4982-44E8-9D7B-78B51E89D07F Q37277536-96C26C40-6134-4022-82D3-BF223B85BB53 Q37371366-C81767F5-9928-4399-A1A7-EEDAF8095568 Q37416147-36BFD040-04B9-4142-A432-879204DE73A6 Q37578490-2CA5EF5A-961C-4F47-8FCC-DC5CF86E7C73 Q37710820-6C3C3A8A-AA98-4A24-BC3B-CDA1B067DE7A Q37946113-5A6A243A-07E0-4E81-AEDD-75E5973188D6 Q38112214-32964891-D614-4FC1-8999-60FA0280C917 Q38166648-E4293AD4-E339-4C9F-9167-9E7AA283E0F1 Q38649157-9AB12CE3-74C5-4FDC-8FE3-E3A5327D9837 Q38669532-7165C14C-765C-40D1-923C-516A6B0AEDE8 Q38942851-078A8CBE-53E4-4FFB-A4CF-FB74517605F7 Q38997247-93065B77-38B0-49E1-813E-CB1BA0EAAD97 Q38999345-259BFF4D-9A05-4787-B636-FF8993E2FF01 Q39288979-0FD2C3F3-98FE-4505-AB89-D5A0E996FCD9 Q39302042-FAFE01ED-85F7-47C5-8DCE-0872F9EBF5C7 Q39617892-A8C111EB-4472-422C-8B08-C8BF07B7D4AB Q39654588-8407DEF2-06EA-4441-9C8E-FA31CAFC636E Q39685068-83DD455F-B356-4B70-9307-E106FDE7C6BB Q39880344-08FD0AE3-CECE-4747-BA92-ED38CCEE6200 Q39923388-8A5463E6-162C-4453-AB7C-B8E29C92ECD1 Q40009062-8FFD62BC-2621-4486-9A06-3EB54C73F8D0 Q40081356-EC053280-CC59-4B22-8709-96B91764184A

P2860

Comparison of the capability of GDNF, BDNF, or both, to protect nigrostriatal neurons in a rat model of Parkinson's disease.

http://www.wikidata.org/entity/Q36969309

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

2005年论文

@zh

2005年论文

@zh-cn

name

Comparison of the capability o ...... model of Parkinson's disease.

@en

type

label

Comparison of the capability o ...... model of Parkinson's disease.

@en

prefLabel

Comparison of the capability o ...... model of Parkinson's disease.

@en

P1433

Q36969309-35E47C16-E9A9-4998-8996-A71545DD4573

P1476

Q36969309-E88BC563-F026-436D-B5F2-A6E913C547DF

P2093

Q36969309-3326BAB1-59B9-4816-8804-5DEB6BB5DF6D

Q36969309-393E9820-18A9-4D3D-B8DF-50D90EF81D76

Q36969309-53DA129B-E40C-4121-BA9E-BEE6F3188E35

Q36969309-573A8C47-6C63-46AF-8D43-121F6FC999F7

Q36969309-74E52224-D6AA-4C17-BC3D-146A33F871C4

Q36969309-9C2CFA69-46EE-42F7-BA76-05847AF820D5

P2860

Q36969309-0F7DACFF-46A8-4736-A2BB-A573BF77C448

Q36969309-14054993-3B6E-4110-9CAE-470112FF0A25

Q36969309-27FC6837-773F-438D-BEDC-CC325487843A

Q36969309-2B4DA9CE-946D-42F5-AE28-938DF282F6B7

Q36969309-2E579CED-AE91-44F1-BDE8-9B8ADD901D9A

Q36969309-385C4D6E-6643-4CEF-85ED-50A865E9939E

Q36969309-3AD76EA0-5A24-4571-875B-5598051DCB2E

Q36969309-3F4EB3B3-1D1C-48A2-9E87-29E4AA2920CA

Q36969309-43B27A9E-3CEB-46CC-9B1B-D003D4FCBA3F

Q36969309-46137A96-8C77-4D81-BBDD-F34043BFEEB0

P304

Q36969309-B89B6FEA-88D1-43FA-8220-2A64EC13BB3A

P31

Q36969309-02A08DE9-AE27-42D2-8FAD-3528CDBF5ECA

P356

Q36969309-530680DC-633C-491B-B79E-B49374FCFF67

P407

Q36969309-048BE27E-3FF8-404F-BD44-4360EF20F54B

P433

Q36969309-FAFFE850-724F-447E-BED4-1850A1BAC0CE

P478

Q36969309-1961DD2A-818A-420C-8D2A-98B9606613AF

P577

Q36969309-5D7DD25E-34BF-4E63-AF73-C8D200E2B1A8

P5875

Q36969309-634D65D5-0D6F-4E01-9F23-568D87DB9231

P698

Q36969309-D92A59F1-B1BA-4E26-9F2E-B9D82A1AB3BC

P921

Q36969309-75E11813-487E-40D4-83DC-76591CD8FB90

P932

Q36969309-847935BC-DEC4-4D90-A6B0-A69C4CD46696

P356

J.BRAINRES.2005.05.072

P1433

P1476

Comparison of the capability o ...... model of Parkinson's disease.

@en

P2093

Alfred I Geller

http://www.w3.org/2001/XMLSchema#string

Lingxin Kong

http://www.w3.org/2001/XMLSchema#string

Mei Sun

http://www.w3.org/2001/XMLSchema#string

Qingsheng Gao

http://www.w3.org/2001/XMLSchema#string

Xiaodan Wang

http://www.w3.org/2001/XMLSchema#string

Xiu-gui Lu

http://www.w3.org/2001/XMLSchema#string

P2860

Functional recovery in parkinsonian monkeys treated with GDNF

GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons

Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease

NeuN, a neuronal specific nuclear protein in vertebrates

Regulated release and polarized localization of brain-derived neurotrophic factor in hippocampal neurons

Aberrant sprouting and downregulation of tyrosine hydroxylase in lesioned nigrostriatal dopamine neurons induced by long-lasting overexpression of glial cell line derived neurotrophic factor in the striatum by lentiviral gene transfer.

Localized striatal delivery of GDNF as a treatment for Parkinson disease.

Reversal of motor impairments in parkinsonian rats by continuous intrastriatal delivery of L-dopa using rAAV-mediated gene transfer

Towards a neuroprotective gene therapy for Parkinson's disease: use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model.

Treatment of parkinsonism with levodopa.

P304

119-129

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.BRAINRES.2005.05.072

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

1052

http://www.w3.org/2001/XMLSchema#string

P577

2005-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7725626

http://www.w3.org/2001/XMLSchema#string

P698

16018990

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease

P932

2581863

http://www.w3.org/2001/XMLSchema#string